恩度联合化疗对Ⅳ期非小细胞肺癌患者临床疗效与肿瘤标志物的影响(1)
[摘要] 目的 探討恩度联合化疗一线治疗Ⅳ期非小细胞肺癌的临床疗效及血清肿瘤标志物的变化。方法 方便选取阳谷县人民医院肿瘤血液内科(2015年1月—2017年1月)诊疗的80例Ⅳ期非小细胞肺癌患者作为研究对象，采用随机的方法分成两组，40例的对照组患者采用的是化疗，40例的观察组患者在对照组基础上给予恩度治疗，对比两组患者临床疗效和疾病无进展生存期以及治疗前后血清肿瘤标志物水平。结果 两组患者临床疗效分别为57.50% vs 30.00%，观察组有效率显著高于对照组患者(χ2=15.365 1，P<0.05)。观察组患者的无进展生存期为(6.59±1.39)个月，显著高于对照组患者的(3.38±1.38)个月(t=10.365 0，P<0.05)。治疗后观察组患者CA125、CYFRA211、CEA水平分别为(55.21±5.40)U/mL、(2.35±0.33)ng/mL、(6.01±0.35)μg/L，明显低于对照组(69.89±8.44)U/mL、(3.24±0.54)ng/mL、(7.61±0.84)μg/L，差异有统计学意义(t=9.266 2、8.894 4、11.120 1， P<0.05)。结论 恩度联合化疗一线治疗可延长患者无进展生存期，因此值得临床推广。
, 百拇医药
[关键词] 恩度;化疗;一线治疗;Ⅳ期非小细胞肺癌;临床疗效;肿瘤标志物
[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-0742(2019)09(a)-0022-03
[Abstract] Objective To investigate the clinical efficacy and serum tumor markers of patients with stage IV non-small cell lung cancer treated with Endotherapy combined with chemotherapy. Methods Convenient select eighty patients with stage IV non-small cell lung cancer who were treated by Department of Oncology and Blood Medicine of Yanggu County People's Hospital (January 2015 to January 2017) were enrolled in the study. They were randomly divided into two groups and 40 patients in the control group， chemotherapy was used， and 40 patients in the observation group were treated with endotherapy on the basis of the control group. The clinical efficacy and disease progression-free survival and serum tumor marker levels before and after treatment were compared between the two groups. Results The clinical efficacy of the two groups was 57.50% vs 30.00%， and the effective rate of the observation group was significantly higher than that of the control group (χ2=15.365 1， P<0.05). The progression-free survival of the observation group was (6.59±1.39)months， which was significantly higher than that of the control group (3.38±1.38)months(t=10.365 0， P<0.05). After treatment， the levels of CA125， CYFRA211， and CEA in the observation group were (55.21±5.40)U/mL， (2.35±0.33)ng/mL， and (6.01±0.35)μg/L， which were significantly lower than those in the control group (69.89±8.44)U/mL， (3.24±0.54)ng/mL， (7.61±0.84)μg/L， the difference was statistically significant (t=9.266 2， 8.894 4， 11.120 1， P<0.05). Conclusion Endotherapy combined with first-line chemotherapy can prolong the progression-free survival of patients， so it is worthy of clinical promotion.
[Key words] Endo; Chemotherapy; First-line treatment; Stage IV non-small cell lung cancer; Clinical efficacy; Tumor markers, 百拇医药(李江)
, 百拇医药
[关键词] 恩度;化疗;一线治疗;Ⅳ期非小细胞肺癌;临床疗效;肿瘤标志物
[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-0742(2019)09(a)-0022-03
[Abstract] Objective To investigate the clinical efficacy and serum tumor markers of patients with stage IV non-small cell lung cancer treated with Endotherapy combined with chemotherapy. Methods Convenient select eighty patients with stage IV non-small cell lung cancer who were treated by Department of Oncology and Blood Medicine of Yanggu County People's Hospital (January 2015 to January 2017) were enrolled in the study. They were randomly divided into two groups and 40 patients in the control group， chemotherapy was used， and 40 patients in the observation group were treated with endotherapy on the basis of the control group. The clinical efficacy and disease progression-free survival and serum tumor marker levels before and after treatment were compared between the two groups. Results The clinical efficacy of the two groups was 57.50% vs 30.00%， and the effective rate of the observation group was significantly higher than that of the control group (χ2=15.365 1， P<0.05). The progression-free survival of the observation group was (6.59±1.39)months， which was significantly higher than that of the control group (3.38±1.38)months(t=10.365 0， P<0.05). After treatment， the levels of CA125， CYFRA211， and CEA in the observation group were (55.21±5.40)U/mL， (2.35±0.33)ng/mL， and (6.01±0.35)μg/L， which were significantly lower than those in the control group (69.89±8.44)U/mL， (3.24±0.54)ng/mL， (7.61±0.84)μg/L， the difference was statistically significant (t=9.266 2， 8.894 4， 11.120 1， P<0.05). Conclusion Endotherapy combined with first-line chemotherapy can prolong the progression-free survival of patients， so it is worthy of clinical promotion.
[Key words] Endo; Chemotherapy; First-line treatment; Stage IV non-small cell lung cancer; Clinical efficacy; Tumor markers, 百拇医药(李江)